Floatz logo

Emavusertib

Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

74 Active assets in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cytarabine
National Cancer Institute (NCI)
Phase 3BBB
Nivestim
City of Hope Medical Center
Phase 2/3BBB
Idarubicin
Fred Hutchinson Cancer Center
Phase 2/3BB
Etoposide
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Emavusertib is also rated in:

acute myeloid leukemiaActive
B
Indicative · Phase 2
58 / 100
View asset →
myelodysplastic syndromeActive
CCC
Indicative · Phase 2
55 / 100
View asset →
acute myeloid leukemia with multilineage dysplasiaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →